A-Alpha Bio Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
35
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$22.4M
- Investors
-
18
A-Alpha Bio General Information
Description
Developer of synthetic biotechnology and machine learning designed to accelerate drug development with synthetic biology and next-generation sequencing. The company's biotechnology measures interactions between biologics libraries and multiple targets in a single experimental step that reduces time spent and cost while improving success rates, enabling researchers to discover, optimize, and characterize drugs in an enhanced way.
Contact Information
Website
www.aalphabio.comCorporate Office
- 2101 4th Avenue
- Suite 500
- Seattle, WA 98121
- United States
Corporate Office
- 2101 4th Avenue
- Suite 500
- Seattle, WA 98121
- United States
A-Alpha Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series A2) | 25-Jul-2023 | $22.4M | Completed | Pre-Clinical Trials | ||
| 8. Early Stage VC (Series A) | 08-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 7. Grant | 09-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 6. Seed Round | 13-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 30-May-2019 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 01-Jul-2018 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 25-Jul-2017 | Completed | Startup | |||
| 2. Grant | 25-May-2017 | $52.5K | Completed | Startup | ||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
A-Alpha Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed-1 | 187,549 | $0.000100 | 6% | $2.63 | $2.63 | 1x | $2.63 | 1.93% |
| Seed | 930,620 | $0.000100 | 6% | $2.63 | $2.63 | 1x | $2.63 | 9.58% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
A-Alpha Bio Comparisons
Industry
Financing
Details
A-Alpha Bio Competitors (33)
One of A-Alpha Bio’s 33 competitors is Vividion Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| BigHat Biosciences | Venture Capital-Backed | San Mateo, CA | ||||
| Onyx | Venture Capital-Backed | Berkeley, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Integral Molecular | Private Debt Financed | Philadelphia, PA |
A-Alpha Bio Patents
A-Alpha Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250372208-A1 | Synthetic augmentation of multiple sequence alignment of protein-protein interactions | Pending | 31-May-2024 | ||
| WO-2025251028-A1 | Synthetic augmentation of multiple sequence alignment of protein-protein interactions | Pending | 31-May-2024 | ||
| US-12281147-B2 | Interleukin 21 variants | Active | 14-Aug-2023 | ||
| US-20250059247-A1 | Interleukin 21 variants | Active | 14-Aug-2023 | ||
| WO-2025038726-A2 | Interleukin 21 variants | Inactive | 14-Aug-2023 | C07K14/54 |
A-Alpha Bio Signals
A-Alpha Bio Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Breakout Ventures | Venture Capital | Minority | ||
| Lux Capital | Venture Capital | Minority | ||
| Perceptive Advisors | Venture Capital | Minority | ||
| Xontogeny | Accelerator/Incubator | Minority | ||
| AME Cloud Ventures | Venture Capital | Minority |
A-Alpha Bio FAQs
-
When was A-Alpha Bio founded?
A-Alpha Bio was founded in 2017.
-
Where is A-Alpha Bio headquartered?
A-Alpha Bio is headquartered in Seattle, WA.
-
What is the size of A-Alpha Bio?
A-Alpha Bio has 35 total employees.
-
What industry is A-Alpha Bio in?
A-Alpha Bio’s primary industry is Drug Discovery.
-
Is A-Alpha Bio a private or public company?
A-Alpha Bio is a Private company.
-
What is the current valuation of A-Alpha Bio?
The current valuation of A-Alpha Bio is .
-
What is A-Alpha Bio’s current revenue?
The current revenue for A-Alpha Bio is .
-
How much funding has A-Alpha Bio raised over time?
A-Alpha Bio has raised $45.6M.
-
Who are A-Alpha Bio’s investors?
Breakout Ventures, Lux Capital, Perceptive Advisors, Xontogeny, and AME Cloud Ventures are 5 of 18 investors who have invested in A-Alpha Bio.
-
Who are A-Alpha Bio’s competitors?
Vividion Therapeutics, BigHat Biosciences, Onyx, Arvinas, and Integral Molecular are some of the 33 competitors of A-Alpha Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process